Dr. Amy O. Wisse

Dr. Daniel Judge is a professor of medicine in cardiology at MUSC. He received his medical degree at the University of Pennsylvania, and did his post-graduate training in internal medicine, cardiology, and advanced heart failure/transplant cardiology at Johns Hopkins. He is board-certified in both cardiology and advanced heart failure/transplant cardiology.Dr. Judge takes care of adult patients with inherited forms of cardiovascular disease, as well as congestive heart failure. As director of the cardiovascular genetics program, Dr. Judge has extensive experience caring for individuals and families with inherited forms of cardiomyopathy, aortic aneurysm, amyloidosis, and cardiac involvement from other genetic conditions.He has authored more than 150 scientific manuscripts. Dr. Judge is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Cardiac Amyloidosis, Heart Transplant, and Cardiac Ablation. Dr. Judge is currently accepting new patients.

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections.He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society's Best Practices committee, and as founding co-chair of the CF Foundation's Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis.He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical \& Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations. Dr. Flume is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Cystic Fibrosis, Bronchiectasis, Nontuberculous Mycobacterial Lung Disease, Mycobacterium Avium Complex Infections, and Lung Transplant. Dr. Flume is currently accepting new patients.

Dr. Gerard Silvestri is a professor of medicine and a lung cancer pulmonologist at the Medical University of South Carolina with a career dedicated to the evaluation, management and improvement of outcomes of patients with this most common of malignancies. He completed his undergraduate education at Fairleigh Dickinson University, his medical degree at St. Georges University, a residency in internal medicine at the Hospital of St. Raphaels/Yale University School of Medicine and fellowship training at Dartmouth. He has an advanced degree in health services research, also from Dartmouth.Dr. Silvestri began the first multidisciplinary lung cancer clinic in South Carolina, and now evaluates between five and seven new lung cancers per week. His clinical research is patient-oriented and directed towards nearly every aspect of lung cancer care. He has experience in evaluating new technologies for the diagnosis and staging of lung cancer and was the part of the first group to publish the utility of endoscopic ultrasound with fine needle aspiration of mediastinal lymph nodes to stage lung cancer patients. Dr. Silvestri has been a section editor and author of the American College of Chest Physicians evidence-based guidelines on the diagnosis and management of lung cancer. To date, he has over 200 peer-reviewed journal publications, abstracts, book chapters and invited commentaries in clinical care and research of lung cancer. He has lectured as a master clinician in lung cancer for both the American College of Chest Physicians (ACCP) and the American Thoracic Society (ATS), and has served as chair of the Thoracic Oncology Network of the ACCP. Dr. Silvestri is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Nodules, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Advanced Bronchoscopy. Dr. Silvestri is currently accepting new patients.